| Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1 F Montemurro, P Ellis, A Anton, R Wuerstlein, S Delaloge, J Bonneterre, ... European journal of cancer 109, 92-102, 2019 | 91 | 2019 |
| Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study M Martin-Richard, R Gallego, C Pericay, JG Foncillas, B Queralt, ... Investigational new drugs 31, 1573-1579, 2013 | 82 | 2013 |
| Anorexia–cachexia syndrome in cancer: implications of the ubiquitin–proteasome pathway C Camps, V Iranzo, RM Bremnes, R Sirera Supportive care in cáncer 14, 1173-1183, 2006 | 43 | 2006 |
| Management of malignant insulinoma JC Ferrer-García, V Iranzo González-Cruz, S Navas-DeSolís, ... Clinical and Translational Oncology 15, 725-731, 2013 | 42 | 2013 |
| Update on systemic treatment in early triple negative breast cancer M Núñez Abad, S Calabuig-Fariñas, M Lobo de Mena, ... Therapeutic advances in medical oncology 13, 1758835920986749, 2021 | 33 | 2021 |
| Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy C Camps, R Sirera, V Iranzo, M Tarón, R Rosell Clinical Lung Cancer 8 (6), 369-375, 2007 | 32 | 2007 |
| Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer M Núñez Abad, S Calabuig-Fariñas, M Lobo de Mena, S Torres-Martínez, ... Cancers 14 (2), 307, 2022 | 27 | 2022 |
| A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non … R Garcia-Carbonero, M Benavent, P Jiménez Fonseca, D Castellano, ... Journal of Clinical Oncology 39 (3_suppl), 360-360, 2021 | 24 | 2021 |
| Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non–Small-Cell Lung Cancer Patients E Jantus-Lewintre, R Sirera, A Cabrera, A Blasco, C Caballero, V Iranzo, ... Clinical lung cancer 12 (5), 320-327, 2011 | 24 | 2011 |
| Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial M Quintela-Fandino, E Holgado, L Manso, S Morales, B Bermejo, ... Breast Cancer Research 22, 1-14, 2020 | 21 | 2020 |
| Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity I Iranzo, JM Huguet, P Suárez, L Ferrer-Barceló, V Iranzo, J Sempere World Journal of Gastrointestinal Endoscopy 10 (12), 392, 2018 | 21 | 2018 |
| Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer V Iranzo, RM Bremnes, P Almendros, J Gavilá, A Blasco, R Sirera, ... Lung Cancer 63 (1), 63-67, 2009 | 21 | 2009 |
| Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non–Small-Cell Lung Cancer Patients V Iranzo, R Sirera, RM Bremnes, A Blasco, E Jantus-Lewintre, M Tarón, ... Clinical lung cancer 12 (4), 224-230, 2011 | 18 | 2011 |
| First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age A Petrillo, A Pappalardo, F Calabrese, G Tirino, L Pompella, J Ventriglia, ... Journal of Gastrointestinal Oncology 10 (5), 910, 2019 | 17 | 2019 |
| Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR [+])/human epidermal growth factor receptor … A Llombart-Cussac, C Harper-Wynne, A Perello, A Hennequin, ... Journal of Clinical Oncology 41 (16_suppl), 1001-1001, 2023 | 16 | 2023 |
| Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial. A Carrato, R Pazo-Cid, T Macarulla, J Gallego, P Jiménez-Fonseca, ... Journal of Clinical Oncology 40 (16_suppl), 4022-4022, 2022 | 16 | 2022 |
| Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a … A Irigoyen, J Gallego, CG Ponce, R Vera, V Iranzo, I Ales, S Arévalo, ... European Journal of Cancer 75, 73-82, 2017 | 15 | 2017 |
| Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer R Sirera, M Gil, A Blasco, A Cabrera, MJ Safont, V Iranzo, D Cayuela, ... Lung Cancer 61 (1), 104-108, 2008 | 14 | 2008 |
| Update on adjuvant hormonal treatment of early breast cancer J Lao Romera, TJ Puertolas Hernández, I Peláez Fernández, ... Advances in therapy 28, 1-18, 2011 | 13 | 2011 |
| 1097O the AXINET trial (GETNE1107): axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs R Garcia-Carbonero, M Benavent, PJ Fonseca, D Castellano, ... Annals of Oncology 32, S907-S908, 2021 | 10 | 2021 |
